Discover Roquette’s unwavering commitment to enabling life-saving pharmaceuticals!

October 24, 2017
Roquette

Sponsored Content

Meet the Roquette pharma team at CPhI Worldwide this year, they have many news to share!

 

Acquisition of ITACEL:
Continuously seeking for better serving its customers worldwide, Roquette has recently enlarged its portfolio of solutions thanks to the acquisition agreement of ITACEL, a leading player in Brazil and Latin America.
ITACEL is BLANVER’ shareholders excipients division. This acquisition will enable to create new opportunities for both ROQUETTE and ITACEL’s customers and employees and to be positioned as a global leader in natural-based pharmaceutical excipients solutions with 4 new ranges of products now available:

  • -MICROCEL®, a partially depolymerized cellulose;

  • -SOLUTAB®, a highly efficient superdisintegrant;

  • -TABULOSE® SC, a co-processed product composed of Microcrystalline Cellulose (MCC) and Sodium

  • -Carboxymethylcellulose (CMC),

  • -EXPLOSOL®, a superdisintegrant with an action mechanism based on water absorption.

 

Biopharma segment launch:
Recently committed to the Biopharma* market, Roquette is ready to help formulators bringing new biologics to life.
Thanks to a unique sole custody of the supply chain, Roquette now offers multi-compendial grade materials for both upstream and downstream applications.
Four new brands coming to the market under the names LYCADEX® BioPharma dextrose, PEARLITOL® BioPharma mannitol, NEOSORB® BioPharma sorbitol and Dextrose Anhydrous BioPharma.

 

Opening a new facility in Singapore in the fall of 2017:
A new Research & Development and Customer Technical Service facility in Singapore will complement ROQUETTE’s deep expertise in formulation and application science, giving customers throughout Asia the ability to receive localized project support and in-depth application training.

 

The new R&D and CTS facility will be a key asset to support the ROQUETTE’s Pharma Business Unit growth ambitions, and there are expansion plans for a Biopharma lab.

 

From oral dosage excipients (Rx, Gx, nutraceuticals & OTC) and biopharma materials to injectables and dialysis solutions, Roquette is holding itself to the highest industry standards - providing consistency and reliability across every ingredient.

 

To learn more about our latest news, come and visit us on our booth for a cocktail party!

(*) Biopharma: The Protein-based drugs can be game-changing by having the ability to put rheumatoid arthritis into remission and transform many cancers into treatable conditions.

 

About RoquetteA family-owned Group serving customers globally, Roquette is a leader in specialty food ingredients and pharmaceutical excipients. The products and solutions developed by the Group deliver proven technological, nutritional and health benefits precisely tailored to the pharma, nutrition, food and selected industry markets. Roquette’s offer is produced from plant-based raw materials such as corn, wheat, potatoes and peas. Since its foundation over 80 years ago, the Group’s growth has been based on innovation, a passion for the job and a commitment to achieve. Roquette operates in over 100 countries, has a turnover of around 3.2 billion euros and currently employs more than 8,300 people worldwide.

 

Contact Details:

Roquette
62080 LESTREM
FRance
Website:www.roquette.com
E-mail:stephanie.delobelle@roquette.com